Lawrence A Kenyon's Net Worth

$553 Thousand

Estimate Recalculated Sep 8, 2024 07:29PM EST

Who is Lawrence A Kenyon?

Lawrence A Kenyon does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include ALFACELL CORP, Outlook Therapeutics, Inc., PAR PHARMACEUTICAL COMPANIES, INC., Arno Therapeutics, Inc, and NEOPHARM INC.

SEC CIK

Lawrence A Kenyon's CIK is 0001230484

Past Insider Trading and Trends

2007 was Lawrence A Kenyon's most active year for acquiring shares with 7 total transactions. Lawrence A Kenyon's most active month to acquire stocks was the month of March. 2010 was Lawrence A Kenyon's most active year for disposing of shares, totalling 21 transactions. Lawrence A Kenyon's most active month to dispose stocks was the month of February. 2004 saw Lawrence A Kenyon paying a total of $398,200.00 for 20,000 shares, this is the most they've acquired in one year. In 2010 Lawrence A Kenyon cashed out on 50,087 shares for a total of $733,362.11, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

ALFACELL CORP No price found

President, CEO and CFO

Lawrence A Kenyon owns 25,000 units of Common Stock. In the year 2007 Lawrence A Kenyon filed a total of 5 filings.

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Jul 23
Form 3
—
0
—
—
0
Form 4
∞
25K
$2.14
$53,381.32
25K
Apr 11
Form 4
—
0
—
—
0
Jan 16
Form 3
—
0
—
—
0
No matching records found

Outlook Therapeutics, Inc. (OTLK) Snapshot price: $7.95

CHIEF FINANCIAL OFFICER

Lawrence A Kenyon owns 18,926 units of Common Stock which is worth $150,461.70. From 2016 to 2024 Lawrence A Kenyon acquired a total of 85,000 shares in Outlook Therapeutics, Inc. at a cost of $40,680.00, Lawrence also disposed a total of 38,965 shares of Outlook Therapeutics, Inc. equalling to $42,963.65.

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Mar 20
Form 4
+112.03%
10K
$1.83
$18,300.00
18.93K
Apr 20
Form 4
—
0
—
—
0
Oct 1
Form 4
—
0
—
—
0
Jul 17
Form 4
—
0
—
—
0
Mar 19
Form 4/A
-13.14%
-1.35K
$1.70
-$2,295.00
8.93K
Sep 18
Form 4
-1.64%
-1.35K
$1.70
-$2,295.00
80.86K
Sep 18
Form 4
—
0
—
—
0
Sep 12
Form 4
—
0
—
—
0
Feb 19
Form 4
+43.70%
25K
$0.90
$22,380.00
82.21K
Feb 7
Form 4
-15.00%
-10.10K
$0.87
-$8,807.20
57.21K
Sep 18
Form 4
—
0
—
—
0
Aug 1
Form 4
-27.99%
-26.16K
$1.13
-$29,566.45
67.31K
Dec 22
Form 4
+115.00%
50K
—
—
93.48K
Dec 21
Form 3/A
—
0
—
—
0
Form 3
—
0
—
—
0
No matching records found

PAR PHARMACEUTICAL COMPANIES, INC. No price found

EVP, Chief Financial Officer

Lawrence A Kenyon owns 14,337 units of Common Stock.acquired a total of 42,985 shares in PAR PHARMACEUTICAL COMPANIES, INC. at a cost of $279,993.34, Lawrence also disposed a total of 28,648 shares of PAR PHARMACEUTICAL COMPANIES, INC. equalling to $733,362.11.

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-30.57%
-6.31K
$26.90
-$169,792.80
14.34K
Aug 2
Form 4
—
0
$19.13
-$260,361.62
20.65K
Mar 3
Form 4
-4.16%
-897.00
$25.88
-$23,214.36
20.65K
Jan 8
Form 4/A
—
0
—
—
0
Jan 4
Form 4
+100.99%
10.83K
—
—
21.55K
Jan 4
Form 4
∞
10.72K
—
—
10.72K
Jan 8
Form 3
—
0
—
—
0
No matching records found

Arno Therapeutics, Inc No price found

Chief Financial Officer

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Feb 24
Form 3
—
0
—
—
0
No matching records found

NEOPHARM INC No price found

CFO and Secretary

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Jan 25
Form 4
—
0
—
—
0
Apr 28
Form 4
—
0
—
—
0
Feb 17
No matching records found